Policy Developments - Shandong Province's health commission has introduced a plan to provide free care services in all public tertiary hospitals by the end of 2025, aiming to enhance patient experience and satisfaction [2] Drug and Device Approvals - The first domestically produced nine-valent HPV vaccine, named Xinkening 9, has been approved for women aged 9-45, with a two-dose regimen for ages 9-17 and a three-dose regimen for ages 18-45. This vaccine is the second nine-valent HPV vaccine globally, breaking a long-standing market monopoly held by Merck [4] - Huayu Pharmaceutical has received a drug registration certificate for injectable polymyxin B sulfate, effective against nearly all Gram-negative bacteria except for a specific strain [5] - AstraZeneca's drug, Imfinzi (durvalumab), has been approved for the treatment of limited-stage small cell lung cancer in adults, based on positive results from the ADRIATIC Phase III clinical trial [6] Capital Markets - Tianchen Biopharmaceuticals has completed over 200 million yuan in Series C financing, which will be used for the clinical development and commercialization of its core pipeline products [8] Industry Events - Kangfang Biotech has denied allegations of selling clinical research drugs, stating that a sales representative misappropriated drugs for a patient without charging any fees [10][11] - Eli Lilly has signed a licensing and development agreement with Camurus to jointly develop long-acting insulin drugs for obesity and diabetes treatment, with potential milestone payments of up to $870 million [12] - Xinghao Pharmaceutical announced that major shareholder Shuanglu Pharmaceutical plans to reduce its stake by up to 1.51% through various trading methods [14]

Group 1: Domestic Vaccine Developments - Wantai Biologics has received approval for its nine-valent HPV vaccine, making it the first domestic nine-valent HPV vaccine in China and the second globally [1] - The approval is significant as it fills a gap in the domestic market, potentially impacting the pricing and competitive landscape of HPV vaccines [1] Group 2: Oncology Drug Approvals - AstraZeneca's drug, Imfinzi (durvalumab), has been approved for use in adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not shown disease progression after platinum-based chemotherapy [2] - The drug is expected to improve survival rates significantly, with over half of the patients achieving a three-year survival milestone [2] Group 3: Compliance Issues in Pharmaceutical Sales - Kangfang Biologics is facing scrutiny after a sales representative allegedly forged documents to obtain anti-cancer drugs intended for clinical research, raising concerns about compliance in sales management [3] - The incident highlights potential vulnerabilities in the company's sales practices and may negatively impact its brand image and market trust [3] Group 4: Clinical Trials for New Vaccines - Baike Biologics has received approval for clinical trials of its recombinant shingles vaccine, aimed at adults aged 40 and above, which could enhance the company's product portfolio and long-term profitability [4] Group 5: Shareholder Actions - Sinovac Biotech's controlling shareholder plans to reduce its stake by up to 3%, which may be interpreted as a signal for profit-taking after a significant stock price increase of over 150% this year [5] - The reduction aims to optimize the company's equity structure and improve liquidity in the secondary market [5]

4、韩国股市迈入牛市， 李在明赢得总统大选提振改革预期。韩国综合指数周三收涨2.66%，创去年8月1日以来新高， 且较4月低点反弹超过20%，投资 者纷纷涌入可能受益于李在明改革与增长议程的股票。控股公司、金融机构及券商股推动指数走高，市场预期李在明最早将于本月推动实施一项旨在提升 股东回报的关键立法改革。 1、 商务部部长王文涛出席巴黎世贸组织小型部长会议。 他表示，贸易战没有赢家，团结才能共赢，携手方可共进。各方要妥善应对单边关税措施 引发的全球贸易失序，坚持运用世贸组织规则通过平等对话和磋商化解贸易纠纷。 中方已向世贸组织提交《关于当前形势下支持多边贸易体制的声 明》， 愿与各方一道维护国际经贸秩序和全球贸易稳定，为世界经济注入更多确定性。 2、 上海合作组织成员国财长和央行行长会议在北京举行。 与会各方支持采取行动深化区域财金合作，在推进成立上合组织开发银行方面取得实质性进 展， 同意建立上合组织财金智库网络， 并探讨了完善本币结算安排和深化数字普惠金融合作等议题。 3、 财政部公示2025年城市更新行动评审结果， 北京、天津、唐山、包头、大连、哈尔滨、苏州、温州、芜湖、厦门、济南、郑州、宜昌、长沙、 ...

北京万泰生物药业股份有限公司 关于公司九价 HPV 疫苗上市许可申请 获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司(以下简称"公司")全资子公司厦门 万泰沧海生物技术有限公司申报的九价人乳头瘤病毒疫苗（大肠埃希菌）（商品 名称：馨可宁 9）获批上市。现将有关情况公告如下： 证券代码：603392 证券简称：万泰生物 公告编号：2025-031 二、九价 HPV 疫苗简介 宫颈癌是女性最常见的恶性肿瘤之一，由高危型 HPV 持续感染引起。宫颈 癌也是目前唯一可有效预防的癌症，最有效和经济的预防方式就是接种 HPV 疫 苗。公司本次获批的九价 HPV 疫苗覆盖 HPV16/18/31/33/45/52/58 七种高危型和 HPV6/11 两种低危型，可预防上述型别人乳头瘤病毒感染引起的相关疾病。 一、《药品注册证书》的主要信息 药品名称：九价人乳头瘤病毒疫苗（大肠埃希菌） 商品名称：馨可宁 9 剂型：注射剂 申请事项：药品注册（境内生产） 上市许可持有人：厦门万泰沧海生物技术有 ...

Group 1: Artificial Intelligence Industry Development - The Ministry of Industry and Information Technology is focusing on promoting the development of the artificial intelligence industry and empowering new industrialization [1] - Emphasis on cultivating leading AI enterprises and supporting specialized and innovative development of small and medium-sized AI companies [1] - Plans to enhance international cooperation in the AI industry while ensuring safety and governance [1] Group 2: New Power System Construction - The National Energy Administration is organizing the first batch of pilot projects for the construction of a new power system [2] - The pilot projects will focus on seven key areas, including grid technology and intelligent microgrids [2] - The initiative aims to integrate energy resources and data centers in regions with favorable energy conditions [2] Group 3: Virtual Asset Derivatives Trading - The Hong Kong Securities and Futures Commission is considering introducing virtual asset derivatives trading for professional investors [3] - The initiative aims to enrich product options in the Hong Kong market while ensuring orderly and transparent trading [3] Group 4: Urban Renewal Actions - The central government plans to support 20 cities, including Beijing and Tianjin, with over 20 billion yuan for urban renewal actions [4][5] - The initiative aims to address infrastructure shortcomings and establish a sustainable urban renewal mechanism [4] Group 5: HPV Vaccine Approval - Wantai Biological Pharmacy announced the approval of its nine-valent HPV vaccine, marking a significant development in the vaccine market [5] - The company is significantly influenced by its major shareholder, Zhong Shanshan, who holds a substantial stake [5] Group 6: Electric Vehicle Market Growth - In May, wholesale sales of new energy passenger vehicles in China reached 1.24 million units, a year-on-year increase of 38% [14] - The growth is attributed to government policies promoting vehicle upgrades and strong performances from various manufacturers [14] Group 7: Investment Opportunities - Foreign investment firms are actively researching A-share companies, with a focus on integrated circuits and other high-tech sectors [10] - The market is showing interest in new energy vehicles and related technologies as potential investment opportunities [13]

（原标题：6月4日重要资讯一览） 重要的消息有哪些 1．财政部公示2025年城市更新行动评审结果，北京、天津、唐山、包头、大连、哈尔滨、苏州、温州、芜湖、厦门、济南、郑州、宜昌、长沙、 广州、海口、宜宾、兰州、西宁、乌鲁木齐等20个城市入围。未来几年，中央财政计划补助超过200亿元，支持这20个城市实施城市更新行动，探 索建立可持续的城市更新机制，补齐城市基础设施的短板弱项。 2．6月4日，国家能源局发布《关于组织开展新型电力系统建设第一批试点工作的通知》，提出围绕构网型技术、系统友好型新能源电站、智能微 电网、算力与电力协同、虚拟电厂、大规模高比例新能源外送、新一代煤电等七个方向开展试点，探索新型电力系统建设新技术、新模式，推动 新型电力系统建设取得突破。 8．近日，深圳市商务局、市发展改革委联合印发《深圳市推动服务贸易和数字贸易高质量发展实施方案》。其中提出，大力发展跨境金融保险服 务。探索建立深圳证券交易所与香港联合交易所会员互联互通机制。支持港澳银行内地分行开办外币银行卡业务以及对除中国境内公民以外客户 的人民币银行卡业务。支持符合条件的香港保险公司在深设立子公司。探索在前海开展私募股权和创业投资份额 ...

Group 1 - The Ministry of Industry and Information Technology is promoting the development of the artificial intelligence industry and empowering new industrialization, focusing on the layout of general large models and industry-specific large models, emphasizing hardware and software adaptation, and accelerating the establishment of high-quality industry data sets to enhance the intelligence level of key product equipment [1] - The Hong Kong Securities and Futures Commission is considering introducing virtual asset derivatives trading for professional investors, encouraging local and international companies to explore innovations and applications of virtual asset technology [1] - The National Energy Administration is organizing the first batch of pilot work for the construction of a new power system, coordinating regional stock and incremental data center green electricity demand and new energy resource conditions, and collaboratively planning the layout of computing power and electricity projects [1] Group 2 - The Ministry of Finance and the Ministry of Housing and Urban-Rural Development are conducting the 2025 annual evaluation for central financial support for urban renewal actions, planning to support 20 cities including Beijing and Tianjin in implementing urban renewal actions [1] - Kingsoft Office continues to appoint Lei Jun as the honorary chairman of the company [1] - Sinovac Biotech's controlling shareholder, Koyi Medicine, plans to reduce its holdings by no more than 3% of the company's shares [1] - Zhongheng Design has reported that the revenue from its "low-altitude economy" and "commercial aerospace" related project designs is relatively small [1] - Lehui International has indicated that its fresh beer business accounts for a small proportion and is still in a loss stage [1] - A portion of the company's directors and supervisors at Aoheng Co., Ltd. reduced their holdings by 153,000 shares during the period of abnormal stock trading according to the reduction plan [1] - Wantai Biological's application for marketing authorization of its nine-valent HPV vaccine has been approved [1]

Core Viewpoint - Wantai Biological's approval of the nine-valent HPV vaccine marks a potential turning point for the company, which has been facing significant performance pressure [2][7]. Company Summary - Wantai Biological's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received approval for the nine-valent HPV vaccine (brand name: Xinkening 9), making it the first domestically approved nine-valent HPV vaccine in China [2]. - The company has passed the GMP compliance inspection for the production line of the nine-valent HPV vaccine, which is a prerequisite for its market launch [2]. - The nine-valent HPV vaccine covers seven high-risk types (HPV 16/18/31/33/45/52/58) and two low-risk types (HPV 6/11), aimed at preventing related diseases caused by these virus types [5][6]. - The vaccine is suitable for females aged 9 to 45, with a two-dose regimen for ages 9 to 17 and a three-dose regimen for ages 18 to 45 [6]. Industry Summary - The nine-valent HPV vaccine is expected to enhance Wantai Biological's product line and core competitiveness, providing a solid foundation for sustainable development [6]. - The market for high-valent HPV vaccines is anticipated to expand due to increasing public health awareness and consumer purchasing power [6]. - Wantai Biological's financial performance has been under pressure, with a significant decline in revenue and net profit for 2023 and 2024, attributed to market adjustments and government procurement policies [7]. - Other companies, including Shanghai Bowei, Jiangsu Ruike, Watson Bio, and Kangle Health, are also competing in the nine-valent HPV vaccine market, indicating a potential increase in market competition [7].

Company Announcements - Hainan Huatie is planning to issue shares overseas (S shares) and list on the Singapore Exchange, with discussions ongoing with relevant intermediaries [2] - Wantai Biological's subsidiary has received approval for the listing of its nine-valent HPV vaccine, which is the first domestically approved nine-valent HPV vaccine and the second globally [3] - Huamao Technology intends to purchase the remaining 57.84% stake in Fuchuang Youyue, with the transaction constituting a major asset restructuring [4] - Bangji Technology has suspended trading due to planning a significant matter, which involves acquiring 100% of Shandong Beixi Agricultural and Animal Husbandry Co., Ltd. and 80% of Paistong Livestock Technology Consulting (Shanghai) Co., Ltd. [6] - Zhongke Electric plans to invest no more than 8 billion yuan to establish a lithium-ion battery anode material integrated base project in Oman, with an annual production capacity of 200,000 tons [5] Shareholding Changes - ST Jinbi is planning a change in control, leading to a suspension of its stock [16] - Weijie Chuangxin's shareholder plans to reduce their stake by up to 3% due to funding needs [9] - Kexing Pharmaceutical's controlling shareholder intends to reduce their stake by up to 3% to optimize the company's equity structure [14] - Lier Chemical's shareholder plans to reduce their stake by up to 3% [15] Stock Price Movements - Lehui International's stock has experienced abnormal fluctuations, with its beer business currently in a loss phase [10] - Zhongheng Design's stock has also seen abnormal fluctuations, with low revenue from its "low-altitude economy" and "commercial aerospace" projects [11] - Nanhua Futures' stock is facing uncertainty regarding its H-share issuance and listing on the Hong Kong Stock Exchange [12] Contracts & Project Bids - China Electric Power Construction announced that its subsidiary led a consortium that won a 6.282 billion yuan energy storage project [17]

在国产HPV九价疫苗竞速中，万泰生物抢到首发位。 6月4日，万泰生物（SH603392，股价71.24元，市值901亿元）宣布公司旗下九价人乳头瘤病毒疫苗 （大肠埃希菌）（商品名：馨可宁9）获批上市，打破默沙东在人乳头瘤病毒（HPV）九价疫苗领域的 垄断地位。万泰生物的九价疫苗为我国第一款、全球第二款九价HPV疫苗。 在九价HPV疫苗整体接种量下滑的大背景下，一场存量争夺战或将展开。 据了解，这款国产九价HPV疫苗为厦门大学、翔安创新实验室夏宁邵团队和万泰生物联合研制。此前， 万泰生物获批的二价HPV疫苗就由万泰生物携手夏宁邵团队研发。 2007年，团队成员便开始投入到九价HPV疫苗的研发工作中，历时18年研制成功。自2019年起，九价 HPV疫苗已在全国开展了5项临床试验，累计纳入1.1万余名9~45岁健康志愿者。 在18~45岁女性中开展的大规模随机对照Ⅲ期临床试验结果显示，九价疫苗继承了二价疫苗对HPV16、 18型感染和病变的保护，对于二价疫苗未能覆盖的HPV31、33、45、52和58型相关持续感染（12个月以 上）的保护率超过98%，其中针对宫颈部位感染的保护率为100%。在整个临床研究观察期间， ...